The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

TUESDAY, May 13, 2025 (HealthDay News) — U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

The FDA and CDC are investigating reports of serious adverse events, including deaths, in recipients of Ixchiq.

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Postmarketing reports indicate 17 serious adverse events have been reported in vaccine recipients 62 to 89 years old. Due to an ongoing investigation of serious adverse events, it is recommended ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.